CoChat

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia

Open access
Li, M, Seiser, E L, Baldwin, R M, Ramirez, J, Ratain, M J, Innocenti, F, Kroetz, D L · 2018 · The Pharmacogenomics Journal
Cited by 50

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Neutropenia is a common dose-limiting toxicity associated with irinotecan treatment. Although UGT1A1 variants have been associated with neutropenia, a fraction of neutropenia risk remains unaccounted for. To identify additional genetic markers contributing to variability in irinotecan pharmacokinetics and neutropenia, a regression analysis was performed in 78 irinotecan-treated patients to analyze comprehensively three hepatic efflux transporter genes (ABCB1, ABCC1 and ABCG2). rs6498588 (ABCC1) and rs12720066 (ABCB1) were associated with increased SN-38 exposure, and rs17501331 (ABCC1) and rs12720066 were associated with lower absolute neutrophil count nadir. rs6498588 and a variant in high linkage disequilibrium are located in transcriptionally active regions or are predicted to alter transcription factor binding sites. While enhancer activity was not evident in vitro for genomic regions containing these single-nucleotide polymorphisms, rs6498588 was significantly associated with ABCC1 expression in human liver. These results suggest that genetic variation in ABCC1 and ABCB1 may contribute to irinotecan-induced neutropenia by altering expression of transporters involved in irinotecan metabolite disposition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/tpj.2016.75

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 58

  1. de Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994; 54: 4347–4354.
  2. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR . Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21: 807–814. · DOI · Paper page
  3. Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC . Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 1997; 25: 1157–1164.
  4. Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A et al. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 2007; 47: 78–86. · DOI
  5. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382–1388. · DOI · Paper page
  6. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 2007; 17: 497–504. · DOI · Paper page
  7. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24: 2237–2244. · DOI · Paper page
  8. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847–854. · DOI · Paper page
  9. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921–6926.
  10. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenom J 2002; 2: 43–47. · DOI · Paper page
  11. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E . Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10: 5151–5159. · DOI · Paper page
  12. McLeod HL, Parodi L, Sargent DJ, Marsh S, Green E, Abreu P et al. UGT1A1*28, toxicity and outcome in advanced colorectal cancer: results from trial N9741. J Clin Oncol 2006; 24 (Suppl 18): abstract 3520. · doi:10.1200/jco.2006.24.18_suppl.3520
  13. Côté JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13: 3269–3275. · DOI
  14. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27: 2604–2614. · DOI · Paper page
  15. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009; 27: 2530–2535. · DOI · Paper page
  16. Crona DJ, Ramirez J, Qiao W, de Graan AJ, Ratain MJ, van Schaik RH et al. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenom J 2015; 16: 54–59. · DOI
  17. Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK et al. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol 2014; 32: 2328–2334. · DOI
  18. Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M . UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91: 678–682. · DOI · Paper page
  19. Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 2009; 27: 5519–5528. · DOI
  20. Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S et al. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J Gastroenterol 2009; 15: 5058–5066. · DOI
  21. Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9: 3246–3253.
  22. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110: 138–147. · DOI · Paper page
  23. Han JY, Lim HS, Park YH, Lee SY, Lee JS . Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 2009; 63: 115–120. · DOI
  24. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD . Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003; 6: 71–84. · DOI · Paper page
  25. Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003; 13: 741–757. · DOI
  26. Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenom J 2011; 11: 61–71. · DOI
  27. Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T et al. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol 2010; 66: 95–105. · doi:10.1007/s00280-009-1138-y
  28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575. · DOI · Paper page
  29. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57–74. · DOI · Paper page
  30. Roadmap Epigenomics Consortium Roadmap Epigenomics Consortium Kundaje A Roadmap Epigenomics Consortium Meuleman W Roadmap Epigenomics Consortium Ernst J Roadmap Epigenomics Consortium Bilenky M Roadmap Epigenomics Consortium Yen A et al. Integrative analysis of 111 reference human epigenomes. Nature 2015; 518: 317–330. · DOI · Paper page
  31. Kel AE, Gössling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, Wingender E . MATCH: a tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res 2003; 31: 3576–3579. · DOI · Paper page
  32. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M et al. Primer3—new capabilities and interfaces. Nucleic Acids Res 2012; 40: e115. · DOI · Paper page
  33. Koressaar T, Remm M . Enhancements and modifications of primer design program Primer3. Bioinformatics 2007; 23: 1289–1291. · DOI · Paper page
  34. Simonet WS, Bucay N, Lauer SJ, Taylor JM . A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J Biol Chem 1993; 268: 8221–8229. · DOI · Paper page
  35. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genom 2011; 21: 152–161. · DOI · Paper page
  36. Létourneau IJ, Deeley RG, Cole SP . Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genom 2005; 15: 647–657. · DOI
  37. Yee SW, Chen L, Giacomini KM . Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics 2010; 11: 475–479. · DOI
  38. Hesselson SE, Matsson P, Shima JE, Fukushima H, Yee SW, Kobayashi Y et al. Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS One 2009; 4: e6942. · DOI
  39. Choi JH, Yee SW, Kim MJ, Nguyen L, Lee JH, Kang JO et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genom 2009; 19: 770–780. · doi:10.1097/fpc.0b013e328330eeca
  40. Tahara H, Yee SW, Urban TJ, Hesselson S, Castro RA, Kawamoto M et al. Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5). J Pharmacol Exp Ther 2009; 329: 262–271. · DOI
  41. Yee SW, Shima JE, Hesselson S, Nguyen L, De Val S, Lafond RJ et al. Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2). J Pharmacol Exp Ther 2009; 328: 699–707. · doi:10.1124/jpet.108.147207
  42. To KK, Zhan Z, Litman T, Bates SE . Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol 2008; 28: 5147–5161. · DOI · Paper page
  43. Pan YZ, Morris ME, Yu AM . MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009; 75: 1374–1379. · DOI · Paper page
  44. Kim MJ, Skewes-Cox P, Fukushima H, Hesselson S, Yee SW, Ramsey LB et al. Functional characterization of liver enhancers that regulate drug-associated transporters. Clin Pharmacol Ther 2011; 89: 571–578. · DOI
  45. O'Brien VP, Bokelmann K, Ramírez J, Jobst K, Ratain MJ, Brockmöller J et al. Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene. J Pharmacol Exp Ther 2013; 347: 181–192. · DOI
  46. Poonkuzhali B, Lamba J, Strom S, Sparreboom A, Thummel K, Watkins P et al. Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab Dispos 2008; 36: 780–795. · DOI
  47. Zhou Q, Sparreboom A, Tan EH, Cheung YB, Lee A, Poon D et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 2005; 59: 415–424. · DOI
  48. Iyer L, Ramírez J, Shepard DR, Bingham CM, Hossfeld DK, Ratain MJ et al. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol 2002; 49: 336–341. · DOI
  49. Tagen M, Zhuang Y, Zhang F, Harstead KE, Shen J, Schaiquevich P et al. P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett 2010; 4: 195–201. · doi:10.2174/187231210792928251
  50. Chen ZS, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K et al. ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 1999; 55: 921–928. · doi:10.1124/mol.55.2.288 · Paper page
  51. Roelofsen H, Vos TA, Schippers IJ, Kuipers F, Koning H, Moshage H et al. Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 1997; 112: 511–521. · DOI
  52. Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 2000; 922: 188–194. · DOI
  53. Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer 2004; 109: 858–854. · DOI · Paper page
  54. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002; 1: 611–616.
  55. Phelps MA, Sparreboom A . Irinotecan pharmacogenetics: a finished puzzle? J Clin Oncol 2014; 32: 2287–2289. · DOI
  56. Fujiwara Y, Minami H . An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics 2010; 11: 391–406. · DOI
  57. Marsh S, Hoskins JM . Irinotecan pharmacogenomics. Pharmacogenomics 2010; 11: 1003–1010. · DOI
  58. Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, Innocenti F . Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics 2009; 10: 1139–1146. · doi:10.2217/pgs.09.35

Cited by

Metadata

Authors
Li, M., Seiser, E. L., Baldwin, R. M., Ramirez, J., Ratain, M. J., Innocenti, F., & Kroetz, D. L.
Venue
The Pharmacogenomics Journal
Published
2016-11-15
Volume
18
Issue
1
Pages
35-42
ISSN
  • 1470-269X (ISSN-L)
  • 1473-1150
OpenAlex
W2555615622
Cited by
50
References
5
FWCI
3.70
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.